Informations générales (source: ClinicalTrials.gov)
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism : a Prospective FDG PET Study
Interventional
N/A
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
mai 2024
mai 2026
14 septembre 2025
Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune
encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological
syndromes criteria - at the acute phase, before immunomodulating treatment, or within 10
days of treatment initiation.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP Assistance publique - Hôpitaux de Paris | 13/12/2025 07:38:36 | Contacter | |||
| AP-HP - Hôpital La Pitié-Salpêtrière | |||||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hospital Pitie Salpetriere - 75013 - Paris - France | Aurélie Kas, Pr | 13/12/2025 07:38:36 | Contact (sur clinicalTrials) | ||
Critères
Tous
Inclusion Criteria:
- Age ≥ 18 years old
- Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following
criteria :
1. " Definite limbic autoimmune encephalitis " according to 2016 Graus et al.
criteria
2. " Possible autoimmune encephalitis " according to 2016 Graus et al. criteria
AND typical autoantibody detected in serum or CSF
3. " Probable or certain paraneoplastic neurological syndrome " according to Graus
et al. 2021 criteria (excluding peripheral neurological syndromes)
- Less than 6 months since first neurological symptoms imputable to autoimmune
encephalitis
- Affiliated or entitled to a social security system (except AME)
- Obtaining free, written and informed consent (patient or legal representative or the
close relative)
Exclusion criteria
- History of brain tumor, head trauma, infarction or cerebral hematoma likely to
result in altered cerebral carbohydrate metabolism on PET
- Patients who hae been on immunotherapy (corticosteroid bolus, IVIg, plasma exchange,
endoxan, rituximab or other immunotherapy) fr more than 10 days
- Pregnant or breast-feeding woman
- Ventilated intubated patient
- Absolute contraindication to MRI (Pacemaker, cochlear implant, etc.)
- Presence of cognitive disorders incompatible with goog cooperation with the PET scan
- Algic or agitated patient unable to remain immobile in supine position for 30
minutes
- Deprived of liberty or under a protective measure (guardianship or curatorship)
- Patient taking part in other interventional research involving radiopharmaceutical
injections
- Age ≥ 18 years old
- Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following
criteria :
1. " Definite limbic autoimmune encephalitis " according to 2016 Graus et al.
criteria
2. " Possible autoimmune encephalitis " according to 2016 Graus et al. criteria
AND typical autoantibody detected in serum or CSF
3. " Probable or certain paraneoplastic neurological syndrome " according to Graus
et al. 2021 criteria (excluding peripheral neurological syndromes)
- Less than 6 months since first neurological symptoms imputable to autoimmune
encephalitis
- Affiliated or entitled to a social security system (except AME)
- Obtaining free, written and informed consent (patient or legal representative or the
close relative)
Exclusion criteria
- History of brain tumor, head trauma, infarction or cerebral hematoma likely to
result in altered cerebral carbohydrate metabolism on PET
- Patients who hae been on immunotherapy (corticosteroid bolus, IVIg, plasma exchange,
endoxan, rituximab or other immunotherapy) fr more than 10 days
- Pregnant or breast-feeding woman
- Ventilated intubated patient
- Absolute contraindication to MRI (Pacemaker, cochlear implant, etc.)
- Presence of cognitive disorders incompatible with goog cooperation with the PET scan
- Algic or agitated patient unable to remain immobile in supine position for 30
minutes
- Deprived of liberty or under a protective measure (guardianship or curatorship)
- Patient taking part in other interventional research involving radiopharmaceutical
injections